Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting
“The risk of cancer is strongly associated with HPV infection, with the high-risk strain, HPV 16, accounting for approximately 70% of all cervical cancers and 80% of head and neck cancers associated with HPV infection.1,2 Despite the various therapies currently available, there remains a critical need for new and innovative treatment options for advanced HPV 16-associated cancers,” said
Abstract Title: In Vivo Efficacy and Pharmacodynamic Analysis of RTX-321, an Engineered Allogeneic Artificial Antigen Presenting Red Cell Therapeutic
Abstract Number: LB-082
RTX-321 is an allogeneic, artificial antigen-presenting Red Cell Therapeutic product candidate designed to induce a tumor-specific response by selectively activating and expanding tumor-specific T cells against a target antigen. It is engineered to express an HPV 16 antigen bound to MHC I, along with 4-1BBL and IL-12, on the cell surface to mimic T cell APC interactions and thus activate and expand tumor-specific T cells present within the patient, bypassing the dependence on host APCs typically required for cancer vaccines and eliminating the need for manufacturing patient-derived T cells as with CAR T therapies.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the, our expectations regarding the therapeutic potential of our Red Cell Therapeutics, including RTX-321 for the treatment of HPV 16-positive tumors, the timelines for us to file an IND for RTX-321, and our strategy, business plans and focus, including our plans to present preclinical data at the AACR Annual Meeting. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the development of our Red Cell Therapeutic product candidates and their therapeutic potential and other risks identified in our
1 Saraiya M, et. al., US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. J Natl Cancer Inst. 2015 Jun; 107(6): djv086.
2 Ndiaye, C., et al., HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014; 15: 1319–31.
Lori Melançon, Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
+1 (973) 271-6085
Source: Rubius Therapeutics